153 related articles for article (PubMed ID: 11123376)
1. In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues.
Yamada S; Okura T; Kimura R
J Pharmacol Exp Ther; 2001 Jan; 296(1):160-7. PubMed ID: 11123376
[TBL] [Abstract][Full Text] [Related]
2. In vivo measurement by [3H]Tamsulosin of alpha1 adrenoceptors in rat tissues in relation to the pharmacokinetics.
Yamada S; Ohkura T; Deguchi Y; Kimura R
J Pharmacol Exp Ther; 1999 Jun; 289(3):1575-83. PubMed ID: 10336555
[TBL] [Abstract][Full Text] [Related]
3. Disposition and alpha(1)-adrenoceptor binding characteristics of JTH-601 and its metabolites in rat tissues.
Yamada S; Okura T; Kimura R; Deguchi Y; Suzuki Y; Kobayashi T; Aisaka K
Drug Metab Dispos; 2000 Dec; 28(12):1487-92. PubMed ID: 11095588
[TBL] [Abstract][Full Text] [Related]
4. Alpha-1 adrenoceptor up-regulation induced by prazosin but not KMD-3213 or reserpine in rats.
Zhang L; Taniguchi T; Tanaka T; Shinozuka K; Kunitomo M; Nishiyama M; Kamata K; Muramatsu I
Br J Pharmacol; 2002 Apr; 135(7):1757-64. PubMed ID: 11934817
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand.
Murata S; Taniguchi T; Muramatsu I
Br J Pharmacol; 1999 May; 127(1):19-26. PubMed ID: 10369451
[TBL] [Abstract][Full Text] [Related]
6. Relationship between prostatic alpha(1)-adrenoceptor binding and reduction in intraurethral pressure following continuous infusion of KMD-3213 in rats.
Akiyama K; Tatemichi S; Katayama S; Nakajima M; Oki T; Okura T; Yamada S; Kimura R
Pharmacology; 2002; 64(3):140-7. PubMed ID: 11834890
[TBL] [Abstract][Full Text] [Related]
7. Selective and sustained occupancy of prostatic alpha1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats.
Okura T; Yamada S; Abe Y; Kimura R
J Pharm Pharmacol; 2002 Jul; 54(7):975-82. PubMed ID: 12162717
[TBL] [Abstract][Full Text] [Related]
8. Alpha-1 adrenoceptors: evaluation of receptor subtype-binding kinetics in intact arterial tissues and comparison with membrane binding.
Tanaka T; Zhang L; Suzuki F; Muramatsu I
Br J Pharmacol; 2004 Feb; 141(3):468-76. PubMed ID: 14718262
[TBL] [Abstract][Full Text] [Related]
9. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
Ford AP; Arredondo NF; Blue DR; Bonhaus DW; Jasper J; Kava MS; Lesnick J; Pfister JR; Shieh IA; Vimont RL; Williams TJ; McNeal JE; Stamey TA; Clarke DE
Mol Pharmacol; 1996 Feb; 49(2):209-15. PubMed ID: 8632751
[TBL] [Abstract][Full Text] [Related]
10. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Shibata K; Foglar R; Horie K; Obika K; Sakamoto A; Ogawa S; Tsujimoto G
Mol Pharmacol; 1995 Aug; 48(2):250-8. PubMed ID: 7651358
[TBL] [Abstract][Full Text] [Related]
11. [Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213)].
Tatemichi S; Kobayashi K; Maezawa A; Kobayashi M; Yamazaki Y; Shibata N
Yakugaku Zasshi; 2006 Mar; 126 Spec no.():209-16. PubMed ID: 16518085
[TBL] [Abstract][Full Text] [Related]
12. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature.
Murata S; Taniguchi T; Takahashi M; Okada K; Akiyama K; Muramatsu I
J Urol; 2000 Aug; 164(2):578-83. PubMed ID: 10893647
[TBL] [Abstract][Full Text] [Related]
13. In vivo receptor binding of novel alpha1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia.
Yamada S; Ohkura T; Kimura R; Kawabe K
Life Sci; 1998; 62(17-18):1585-9. PubMed ID: 9585140
[TBL] [Abstract][Full Text] [Related]
14. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model.
Akiyama K; Hora M; Tatemichi S; Masuda N; Nakamura S; Yamagishi R; Kitazawa M
J Pharmacol Exp Ther; 1999 Oct; 291(1):81-91. PubMed ID: 10490890
[TBL] [Abstract][Full Text] [Related]
15. Quantitative imaging in live human cells reveals intracellular alpha(1)-adrenoceptor ligand-binding sites.
Mackenzie JF; Daly CJ; Pediani JD; McGrath JC
J Pharmacol Exp Ther; 2000 Aug; 294(2):434-43. PubMed ID: 10900216
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological properties of the cloned alpha 1A/D-adrenoceptor subtype are consistent with the alpha 1A-adrenoceptor characterized in rat cerebral cortex and vas deferens.
Kenny BA; Naylor AM; Greengrass PM; Russell MJ; Friend SJ; Read AM; Wyllie MG
Br J Pharmacol; 1994 Apr; 111(4):1003-8. PubMed ID: 7913370
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo and in vivo alpha1-adrenoceptor binding characteristics of a novel alpha1L-adrenoceptor antagonist, JTH-601, in rat tissues.
Ohkura T; Yamada S; Tohma A; Kimura R; Aisaka K
Biol Pharm Bull; 1999 Jul; 22(7):687-90. PubMed ID: 10443463
[TBL] [Abstract][Full Text] [Related]
18. Determination of alpha 1-adrenoceptor subtype selectivity by [3H]-prazosin displacement studies in guinea-pig cerebral cortex and rat spleen membranes.
Veenstra DM; van Buuren KJ; Nijkamp FP
Br J Pharmacol; 1992 Sep; 107(1):202-6. PubMed ID: 1358383
[TBL] [Abstract][Full Text] [Related]
19. Effects of castration on contraction and alpha(1)-adrenoceptor expression in rat prostate.
Homma Y; Hamada K; Nakayama Y; Tsujimoto G; Kawabe K
Br J Pharmacol; 2000 Dec; 131(7):1454-60. PubMed ID: 11090120
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo occupancy by tamsulosin of alpha1-adrenoceptors in rat tissues in relation to the plasma concentration.
Ohkura T; Yamada S; Deguchi Y; Kimura R; Matsushima H; Higuchi S; Inagaki O; Honda K; Takenaka T
Life Sci; 1998; 63(24):2147-55. PubMed ID: 9851306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
